Depression, anxiety and multiple sclerosis: Links with alexithymia

2011 ◽  
Vol 26 (S2) ◽  
pp. 1698-1698 ◽  
Author(s):  
J. Aloulou ◽  
C. Hachicha ◽  
R. Masmoudi ◽  
A. Boukhris ◽  
C. Mhiri ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mood State ◽  
Disease Onset ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Long Period ◽  
Prevalence Of Depression ◽  
Degree Of Disability

The aim of our study was to assess the prevalence of depression and anxiety in a population of patients treated for multiple sclerosis (MS) and their link with alexithymia.Method31 patients with MS according to McDonald's criteria, and followed in neurology department took part in the study. All patients were evaluated using a protocol to collect the epidemiological, clinical and evolution of the disease. We used versions of Arabized-Hospital Anxiety and Depression Scale (HADS) to assess the mood state and the Toronto Alexithymia Scale (TAS-20) for alexithymia.Results and commentsParticipants were divided on 18 women and 13 men with a mean age of 39 years. The prevalence of depression and anxiety were 42% and 52% respectively. The prevalence of alexithymia was 43%. The anxiety was correlated with the degree of disability and age of disease onset. Similarly, depression was more frequently observed in patients with higher EDSS, a long period of evolution. A positive correlation was found between alexithymia, depression and anxiety.Our study showed that half of all MS patients have mood disorders. However, depression is the most common and most disabling psychiatric disorder in MS. The place of anxiety should not be neglected because in case of comorbidity with depression, can be an aggravating factor. The frequency of alexitymia is high and appears to be positively correlated with depression and anxiety.

The Risk of Depression and Anxiety in the Post-diagnostic Period of Multiple Sclerosis Measured by Screening Instruments and Structured Interviews

2017 ◽  
Vol 41 (S1) ◽  
pp. S236-S236 ◽  
Author(s):  
H. Hoang ◽  
E. Stenager ◽  
E. Stenager
Keyword(s):  
Multiple Sclerosis ◽  
Depression Scale ◽  
Structured Interview ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Screening Instruments ◽  
Hospital Anxiety ◽  
Structured Interviews ◽  
Clinical Screening ◽  
Competing Interest

ObjectiveTo examine the risk of depression and anxiety in MS patients in the post-diagnostic period by using clinical screening instruments and a diagnostic structured clinical interview.MethodA population of 134 MS patients was examined for the risk of depression and anxiety in the post-diagnostic period of MS using the clinical screening instruments Beck Depression Inventory (BDI) and Hospital Anxiety and Depression Scale (HADS). Within six weeks of diagnosis, patients with cut-off > 12 for BDI and > 7 for HADS were offered a clinical structured interview using the Schedules for Clinical Assessment in Neuropsychiatry/SCAN Version 2.1.ResultsThe prevalence of depressive symptoms and depression in the post-diagnostic period of MS was 49.2% when using the screening instruments, but only 15.2% when using the SCAN interview. For anxiety, the prevalence was 3.4% for both the screening instruments and the SCAN interview in the post-diagnostic period of MS.ConclusionMS patients have a risk of depression and anxiety in the post-diagnostic period of MS, but it is crucial to consider which tools to use in a clinical setting to investigate depression and anxiety in MS patients.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Quality of life, depression, and anxiety of patients undergoing hemodialysis: Significant role of acceptance of the illness

2020 ◽  
Vol 56 (1) ◽  
pp. 40-50
Author(s):  
Marthoenis Marthoenis ◽  
Maimun Syukri ◽  
Abdullah Abdullah ◽  
Teuku M Reza Tandi ◽  
Nadisyah Putra ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Health Practitioners ◽  
Prevalence Of Depression ◽  
Study Setting

Objective Routine dialysis is stressful. It has the possibility of leading to depression and anxiety and also reducing patients’ quality of life. Despite these significant consequences, these comorbidities have been rarely studied among Indonesian patients. This study aims to examine the rate of depression, anxiety, and the role of acceptance of their illness on patients’ quality of life. Method A total of 213 patients undergoing hemodialysis in three general hospitals in Aceh, Indonesia, were included in the study. The presence of depression, anxiety, and the quality of life of each patient was assessed using the hospital anxiety and depression scale and WHO quality of life-BREF questionnaires. Results The prevalence of depression and anxiety was 46% and 30.5%, respectively. Depression was only associated with the presence of anxiety and the duration of hemodialysis. Anxiety was negatively associated with quality of life but positively associated with depression and the prescription of an anxiolytic. Overall quality of life was associated with age, body mass index, the presence of anxiety, and acceptance of the illness. Acceptance of the illness was also independently associated with almost every domain of patients’ quality of life. Conclusions The rates of depression and anxiety among patients undergoing hemodialysis in the current study setting are relatively similar to the rates in other settings. Patients’ acceptance of their illnesses is significantly associated with the occurrence of anxiety and quality of life. Therefore, health practitioners should help patients accept their illnesses and the administration of regular hemodialysis.

scholarly journals Mood Disorders in Levothyroxine-Treated Hypothyroid Women

2019 ◽  
Vol 16 (23) ◽  
pp. 4776 ◽  
Author(s):  
Benjamín Romero-Gómez ◽  
Paula Guerrero-Alonso ◽  
Juan Manuel Carmona-Torres ◽  
Blanca Notario-Pacheco ◽  
Ana Isabel Cobo-Cuenca
Keyword(s):  
Depression Scale ◽  
Anxiety And Depression ◽  
Control Group ◽  
Case Group ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Mood Changes ◽  
Prevalence Of Depression ◽  
Convenience Sampling ◽  
Control Study

Background: Hypothyroidism has several symptoms (weight gain, arrhythmias, mood changes, etc.). The aims of this study were (1) to assess the prevalence of anxiety and depression in levothyroxine-treated hypothyroid women and in women without hypothyroidism; (2) to identify variables associated with anxiety and depression. Methods: A case-control study was performed with 393 women. Case-group: 153 levothyroxine-treated hypothyroid women. Control-group: 240 women without hypothyroidism. Convenience sampling. Instrument: The Hamilton Hospital Anxiety and Depression Scale (HADS), and a sociodemographic questionnaire. Results: The prevalence of anxiety in levothyroxine-treated hypothyroid women was higher than in women without hypothyroidism (29.4% vs. 16.7%, χ2 p < 0.001). The prevalence of depression in the case group was higher than in the control group (13.1% vs. 4.6%, χ2 p < 0.001). Levothyroxine-treated hypothyroid women were more likely to have anxiety (OR = 2.08, CI: 1.28–3.38) and depression (OR = 3.13, IC = 1.45–6.45). Conclusion: In spite of receiving treatment with levothyroxine, women with hypothyroidism are more likely to have depression and anxiety. Health professionals need to assess the mood of women with hypothyroidism. Although levothyroxine is a good treatment for the symptoms of hypothyroidism, it may not be enough to prevent development or persistence of depression and anxiety by itself.

scholarly journals Validation of Mood Measures for People with Multiple Sclerosis

2014 ◽  
Vol 16 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Tessa M. Watson ◽  
Emma Ford ◽  
Esme Worthington ◽  
Nadina B. Lincoln
Keyword(s):  
Multiple Sclerosis ◽  
Depression Scale ◽  
High Sensitivity ◽  
High Specificity ◽  
Anxiety And Depression ◽  
Cutoff Score ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Depression Subscale ◽  
Anxiety Subscale

Background: Valid assessments are needed in order to identify anxiety and depression in people with multiple sclerosis (MS). The objective of this study was to assess the validity of questionnaire measures of mood in people with MS. Methods: People with MS were recruited from a clinic database and asked to complete and return a questionnaire containing the Beck Anxiety Inventory (BAI), Beck Depression Inventory–II (BDI-II), and Hospital Anxiety and Depression Scale (HADS). Those who returned the questionnaire were invited to complete a structured clinical interview, which was blind to the results of the questionnaire. Results: The BDI-II and HADS were both found to be valid measures to detect depression and anxiety in people with MS. An optimum cutoff score of 23 for the BDI-II yielded high sensitivity (85%) and high specificity (76%). An optimum cutoff score of 11 for the HADS demonstrated high sensitivity and specificity for both the Anxiety subscale (sensitivity 90%, specificity 92%) and the Depression subscale (sensitivity 77%, specificity 81%). The BAI had high sensitivity (80%) but poor specificity (46%) for detecting anxiety. Conclusion: The BDI-II and HADS can be used to identify mood disorders in people with MS.

scholarly journals Depression and Anxiety in Women with Polycystic Ovary Syndrome and Its Biochemical Associates

2016 ◽  
Vol 8 (1) ◽  
pp. 44-47 ◽  
Author(s):  
Afshaan Ambreen ◽  
Attia Sheikh ◽  
Numeera Faryad ◽  
Saima Batool ◽  
Farhat ul ain Ahmed
Keyword(s):  
Polycystic Ovary Syndrome ◽  
South Asian ◽  
Polycystic Ovary ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Ovary Syndrome ◽  
Prevalence Of Depression ◽  
Biochemical Assessment

ABSTRACT Objective To assess the prevalence of mood depression and anxiety in women with prospectively diagnosed polycystic ovary syndrome (PCOS). Materials and methods A cohort study at Fatima Memorial Hospital was conducted with a total of 137 patients with PCOS and a similar number of controls, attending gynecology clinic; all participants of the study were required to complete hospital anxiety and depression scale (HADS) questionnaire. Later the biochemical assessment was done between PCOS with depression to PCOS without depression in order to find its associates. Results Study shows an increased prevalence of depression and anxiety in women with PCOS as compared to control, general population. How to cite this article Batool S, Ul ain Ahmed F, Ambreen A, Sheikh A, Faryad N. Depression and Anxiety in Women with Polycystic Ovary Syndrome and Its Biochemical Associates. J South Asian Feder Obst Gynae 2016;8(1):44-47.

scholarly journals Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project)

Cephalalgia ◽  
2013 ◽  
Vol 34 (6) ◽  
pp. 426-433 ◽  
Author(s):  
L Bendtsen ◽  
SB Munksgaard ◽  
C Tassorelli ◽  
G Nappi ◽  
Z Katsarava ◽  
...  
Keyword(s):  
Prophylactic Treatment ◽  
Medication Overuse ◽  
Medication Overuse Headache ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Number Of Patients ◽  
Degree Of Disability ◽  
Midas Questionnaire

Objective The objective of this article is to investigate whether headache-related disability, depression and anxiety can be reduced by detoxification and prophylactic treatment in patients with medication-overuse headache (MOH). Methods Patients with MOH were included from six centres in Europe and Latin America in a seven-month cohort study. Before and six months after treatment, the degree of disability was measured by the Migraine Disability Assessment (MIDAS) questionnaire, while anxiety and depression were measured by the Hospital Anxiety and Depression Scale (HADS). Results A total of 694 patients with MOH were included, of whom 492 completed the study. Headache days were reduced by 58.4% from 23.6 to 9.8 days per month at six months ( p < 0.001). The MIDAS score was reduced by 57.1% from baseline 59.9 to 25.7 ( p < 0.001). Number of patients with depression was reduced by 50.7% from 195 to 96 and number of those with anxiety was reduced by 27.1% from 284 to 207 (both p < 0.001). Conclusions Disability, depression and anxiety were considerably reduced in patients with MOH by detoxification and prophylactic treatment. This emphasises the urgent need for increased awareness about avoiding overuse of headache medications and demonstrates that not only headache frequency but also disability are remarkably improved by adequate intervention.

scholarly journals Distractibility in multiple sclerosis: The role of depression

2016 ◽  
Vol 2 ◽  
pp. 205521731665315 ◽  
Author(s):  
Viral P Patel ◽  
Aaron Zambrana ◽  
Lisa AS Walker ◽  
Nathan Herrmann ◽  
Richard H Swartz ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Regression Analysis ◽  
Cognitive Assessment ◽  
Ecological Validity ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Impaired Performance

The present study assesses the influence of depression and anxiety on the effects of cognitive distracters in people with multiple sclerosis (MS). Participants completed computerized versions of the Symbol Digit Modalities Test (c-SDMT) with ( n = 51) and without ( n = 51) auditory distracters. Based on the Hospital Anxiety and Depression Scale (HADS), 29 (28.4%) and 51 (50%) participants were classified as depressed or anxious, respectively. A regression analysis revealed that depression ( p = 0.034), not anxiety ( p = 0.264), further impaired performance on the c-SDMT, particularly in the presence of distracters. These results suggest that distracter effects are influenced by depression more than anxiety. Given that distracters are ubiquitous in real-world environments, their use in a cognitive assessment adds to the ecological validity of the results.

Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors

2014 ◽  
Vol 41 (5) ◽  
pp. 887-896 ◽  
Author(s):  
Emily McDonough ◽  
Renise Ayearst ◽  
Lihi Eder ◽  
Vinod Chandran ◽  
Cheryl F. Rosen ◽  
...  
Keyword(s):  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Related Factors ◽  
Increased Risk ◽  
Prevalence Of Depression ◽  
Unit Increase ◽  
Fatigue Severity

Objective.(1) To determine the prevalence of depression and anxiety in patients with psoriatic arthritis (PsA) and to identify associated demographic and disease-related factors. (2) To determine whether there is a difference in the prevalence of depression and anxiety between patients with PsA and those with psoriasis without PsA (PsC).Methods.Consecutive patients attending PsA and dermatology clinics were assessed for depression and anxiety using the Hospital Anxiety and Depression Scale. Patients underwent a clinical assessment according to a standard protocol and completed questionnaires assessing their health and quality of life. T tests, ANOVA, and univariate and multivariate models were used to compare depression and anxiety prevalence between patient cohorts and to determine factors associated with depression and anxiety.Results.We assessed 306 patients with PsA and 135 with PsC. There were significantly more men in the PsA group (61.4% vs 48% with PsC) and they were more likely to be unemployed. The prevalence of both anxiety and depression was higher in patients with PsA (36.6% and 22.2%, respectively) compared to those with PsC (24.4% and 9.6%; p = 0.012, 0.002). Depression and/or anxiety were associated with unemployment, female sex, and higher actively inflamed joint count as well as disability, pain, and fatigue. In the multivariate reduced model, employment was protective for depression (OR 0.36) and a 1-unit increase on the fatigue severity scale was associated with an increased risk of depression (OR 1.5).Conclusion.The rate of depression and anxiety is significantly higher in patients with PsA than in those with PsC. Depression and anxiety are associated with disease-related factors.

scholarly journals Depression, anxiety and blood serotonin in patients with multiple sclerosis during Betaferon treatment

2008 ◽  
Vol 7 (5-2) ◽  
pp. 424-427
Author(s):  
T. N. Trushnikova ◽  
T. V. Bajdina
Keyword(s):  
Multiple Sclerosis ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Immunomodulating Therapy ◽  
Blood Serotonin ◽  
Immunoenzyme Analysis ◽  
Multiple Sclerosis Patients

Depression and anxiety were examined by Hospital Anxiety and Depression Scale and Spilberger Scale in 217 multiple sclerosis patients treated by Betaferon. The concentration of blood serotonin was determined by immunoenzyme analysis in 71 of them. The multiple sclerosis patients had progressive high levels of depression ((7,55 ± 3,61) points; р = 0,000) and anxiety ((7,55 ± 3,61) points; р = 0,000), and the decreased blood serotonin concentration ((210 ± 134,2) versus (269 ± 98,8) ng/ml; р = 0,036 in healthy people). The level of anxiety was related to the level of serotonin depression. Betaferon did not correct the affective disorders in multiple sclerosis patients, except the decreasing the degree of anxiety, and did not normalize the level of blood serotonin, that suggest the use of selective serotonin reuptake inhibitors during immunomodulating therapy.

A-121 Functional Outcomes in Bilingual Persons with Traumatic Brain: The Role of Mood

2021 ◽  
Vol 36 (6) ◽  
pp. 1171-1171
Author(s):  
Winter Olmos ◽  
Daniel W Lopez-Hernandez ◽  
Isabel Munoz ◽  
Laura Schierholz ◽  
Rachel A Rugh-Fraser ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Functional Outcomes ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Anxiety Levels ◽  
The Relationship ◽  
Pearson Correlations

Abstract Introduction We examined the relationship between depression and anxiety, language, and functional outcomes in persons with traumatic brain injury (TBI). Methods The sample consisted of 48 acute TBI (ATBI: 23 Spanish-English Bilinguals; 25 English monolinguals), 30 chronic TBI (CTBI: 17 Spanish English Bilinguals; 12 English monolinguals), and 47 healthy comparison (HC: 29 Spanish-English Bilinguals; 18 English monolinguals) participants. The Hospital Anxiety and Depression Scale was used to measure depression (HADS-D) and anxiety (HADS-A). The Mayo Portland Adaptability Inventory-4 (MPAI-4) was used to measure functional outcomes (ability, adjustment, participation). Results An ANCOVA, controlling for age, revealed the ATBI group reported lower anxiety levels compared to the CTBI group, p = 0.034 np2 = 0.06. HC participants demonstrated significantly higher functional ability compared to both TBI groups, p &lt; 0.05, np2 = 0.08–0.19. The ATBI group demonstrated worse participation scores compared to the CTBI and HC groups, p = 0.001, np2 = 0.11. Pearson correlations revealed mood was related to functional status in ATBI monolinguals (HADS-A: r = 0.29–0.64; HADS-D, r = 0.49–0.62). Monolingual participants with ATBI demonstrated correlations between depressive symptoms and functional adjustment (r = 0.57, p = 0.005) and ability (r = 0.44, p = 0.034). For monolinguals with CTBI, HADS-A correlated with functional outcomes, r = 0.60–0.66, p &lt; 0.05. For bilinguals with CTBI, functional outcomes correlated with HADS-A, r = 0.53–0.66, p &lt; 0.05, and HADS-D, r = 0.54–0.66, p &lt; 0.05. For HC monolinguals, functional outcomes correlated with HADS-A, r = 0.53–0.70, p &lt; 0.05, and HADS-D, r = 0.50–0.72, p &lt; 0.05. Finally, for HC bilinguals, functional outcomes correlated with HADS-A, r = 0.59–0.68, p &lt; 0.05. Conclusion Our results suggest that a relationship between anxiety and depressive symptoms is related more to functional outcomes in monolingual TBI survivors compared to bilingual TBI survivors.

Sign in / Sign up

Export Citation Format

Share Document